Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Jiang, Shan Shan ^a   Weng, De Sheng ^a   Wang, Qi Jing ^a   Pan, Ke ^a   Zhang, Yao Jun ^a   Li, Yong Qiang ^a   Li, Jian Jun ^a   Zhao, Jing Jing ^a   He, Jia ^a   Lv, Lin ^a   Pan, Qiu Zhong ^a   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Angiogenesis; Apoptosis; Galectin 3; Hepatocellular carcinoma; Prognostic factor

Indexed keywords

CASPASE 3; CD34 ANTIGEN; GALECTIN 3; MESSENGER RNA; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CAPILLARY DENSITY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HEPATOCELLULAR CARCINOMA CELL LINE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY HEPATOCELLULAR CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING; CELL CYCLE; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; FEMALE; GALECTIN 3; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84910101870     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0273-3     Document Type: Article

References (37)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997, 349:1269-1276. 10.1016/S0140-6736(96)07493-4, 9142060.
2. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005, 23:2892-2899. 10.1200/JCO.2005.03.196, 15860847.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
4. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285. 10.1055/s-2007-1007117, 10518307.
5. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Chang Chien CS, Lee CM, Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMA C1/TEP1 in hepatocellular carcinoma. Cancer 2003, 97:1929-1940. 10.1002/cncr.11266, 12673720.
6. Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG. LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 2007, 12:239-251. 10.1016/j.ccr.2007.07.002, 17785205.
7. Stebbing J, Filipovic A, Giamas G. Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene 2013, 32:4871-4872. 10.1038/onc.2012.591, 23318416.
8. Boscher C, Zheng YZ, Lakshminarayan R, Johannes L, Dennis JW, Foster LJ, Nabi IR. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem 2012, 287:32940-32952. 10.1074/jbc.M112.353334, 22846995.
9. Friedrichs J, Torkko JM, Helenius J, Teravainen TP, Fullekrug J, Muller DJ, Simons K, Manninen A. Contributions of galectin-3 and -9 to epithelial cell adhesion analyzed by single cell force spectroscopy. J Biol Chem 2007, 282:29375-29383. 10.1074/jbc.M701867200, 17675292.
10. Barondes SH, Cooper DN, Gitt MA, Galectins LH. Structure and function of a large family of animal lectins. J Biol Chem 1994, 269:20807-20810. 8063692.
11. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999, 59:6239-6245. 10626818.
12. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10:267-275. 10.1007/s10495-005-0801-y, 15843888.
13. Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004, 19:527-535. 10.1023/B:GLYC.0000014082.99675.2f, 14758076.
14. Patterson RJ, Wang W, Wang JL. Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus. Glycoconj J 2004, 19:499-506. 10.1023/B:GLYC.0000014079.87862.c7, 14758073.
15. Blanquart C, Gueugnon F, Nguyen JM, Roulois D, Cellerin L, Sagan C, Perigaud C, Scherpereel A, Gregoire M. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol 2012, 7:883-889. 10.1097/JTO.0b013e31824c9272, 22729037.
16. Mayoral MA, Mayoral C, Meneses A, IVillalvazo L, Guzman A, Espinosa B, Ochoa JL, Zenteno E, Guevara J. Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Invest 2008, 26:615-623. 10.1080/07357900701837051, 18584353.
17. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. Anticancer Res 2006, 26:1369-1376. 16619546.
18. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S, Asao T, Kuwano H. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 2007, 27:2289-2296. 17695516.
19. Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y, Shimosegawa T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol Res 2008, 38:1098-1111. 10.1111/j.1872-034X.2008.00387.x, 18684128.
20. Eude-Le Parco I, Gendronneau G, Dang T, Delacour D, Thijssen VL, Edelmann W, Peuchmaur M, Poirier F. Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 2009, 19:68-75. 10.1093/glycob/cwn105, 18849326.
21. Deutscher SL, Figueroa SD, Kumar SR. Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl Med Biol 2009, 36:137-146. 10.1016/j.nucmedbio.2008.10.015, 19217525.
22. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010, 176:2067-2081. 10.2353/ajpath.2010.090353, 20363921.
23. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT. Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 1999, 81:519-526. 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-0, 10225438.
24. Peng W, Wang HY, Miyahara Y, Peng G, Wang RF. Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 2008, 68:7228-7236. 10.1158/0008-5472.CAN-08-1245, 18757439.
25. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E, Mordoh J. Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 2006, 168:1666-1675. 10.2353/ajpath.2006.050971, 16651632.
26. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 2006, 12:6709-6715. 10.1158/1078-0432.CCR-06-0758, 17121890.
27. Honjo Y, Nangia-Makker P, Inohara H, Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 2001, 7:661-668. 11297262.
28. Shimamura T, Sakamoto M, Ino Y, Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, Tanaka K, Sekihara H, Hirohashi S. Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002, 8:2570-2575. 12171885.
29. Cheng CL, Hou HA, Lee MC, Liu CY, Jhuang JY, Lai YJ, Lin CW, Chen HY, Liu FT, Chou WC, Chen CY, Tang JL, Yao M, Huang SY, Ko BS, Wu SJ, Tsay W, Tien HF. Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood 2013, 121:3172-3180. 10.1182/blood-2012-07-443762, 23449638.
30. Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, La Sorda R, Spinella F, Bagnato A, Lattanzio R, D'Egidio M, Di Risio A, Stampolidis P, Piantelli M, Natoli C, Ullrich A, Iacobelli S. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med (Berl) 2013, 91:83-94. 10.1007/s00109-012-0936-6.
31. Chen C, Duckworth CA, Zhao Q, Pritchard DM, Rhodes JM, Yu LG. Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res 2013, 19:1693-1704. 10.1158/1078-0432.CCR-12-2940, 23401226.
32. Kim SJ, Shin JY, Lee KD, Bae YK, Choi IJ, Park SH, Chun KH. Galectin-3 facilitates cell motility in gastric cancer by up-regulating protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One 2011, 6:e25103. 10.1371/journal.pone.0025103, 21966428.
33. Braeuer RR, Zigler M, Kamiya T, Dobroff AS, Huang L, Choi W, McConkey DJ, Shoshan E, Mobley AK, Song R, Raz A, Bar-Eli M. Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin. Cancer Res 2012, 72:5757-5766. 10.1158/0008-5472.CAN-12-2424, 22986745.
34. Wang Y, Balan V, Kho D, Hogan V, Nangia-Makker P, Raz A. Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 2013, 32:5058-5065. 10.1038/onc.2012.528, 23160381.
35. Lee YK1, Lin TH, Chang CF, Lo YL. Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma. PLoS One 2013, 8:e82478. 10.1371/journal.pone.0082478, 24303084.
36. Margadant C, van den Bout I, van Boxtel AL, Thijssen VL, Sonnenberg A. Epigenetic regulation of galectin-3 expression by beta1 integrins promotes cell adhesion and migration. J Biol Chem 2012, 287:44684-44693. 10.1074/jbc.M112.426445, 23118221.
37. Zhang D, Chen ZG, Liu SH, Dong ZQ, Dalin M, Bao SS, Hu YW, Wei FC. Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating beta-catenin. Acta Pharmacol Sin 2013, 34:176-184. 10.1038/aps.2012.150, 23103626.